Timestamps:

00:00 Intro

02:00 Why is it important to respond with grace while we’re under pressure?

03:36 How do you think you develop this ability to project poise when in stressful situations?

05:33 Was there a mentor, situation, or experience where it gave you pause and made you think, “Wow, that’s somebody that really showed grace under pressure and leadership abilities.” Is there anybody in your life who comes to mind? 

07:15 Did you find yourself having some of these mental conversations? How did that go for you?  

08:36 Are those two questions (1. Does this make sense? 2. What could possibly go wrong?) that you’ve been using for a number of years, or is this something that has been more recent for you?

10:57 I’m curious about how do you recognize in your own self, how do you notice when you’re getting challenged and keep it on the rails?

14:28 What’s your feedback to the young professionals in our community to collect themselves in their thoughts?

15:45 How do you continue to grow in your professionalism in your ability to be a more effective leader more broadly?

16:29 What does that well mean to you? What does that look like?

19:54 Outro

Resources:

https://domorestories.com/profile.php?handle=jane-hata 

Timestamps:

00:00 Intro

01:05 How did you first get interested in supporting organ transplantation? 

04:53 What are the organs that we can transplant?

06:00 When we are at the Department of Motor Vehicles, we can register as a donor and make our wishes known to our family, is that right?

07:03 If people are interesting in donating a kidney, for example, do they reach out to their local hospital and let them know they are interested in being a donor?

08:50 How does your work in the Histocompatability laboratory, how does it support transplantation? 

10:57 Can you give our audience kind of a flavor of how does this work to do this kind of dance to match donor and recipient and have a successful transplant? 

13:11 What’s on the horizon for HLA and histocompatibility in the next couple of years?

18:30 The ability for us to identify a patient, these patients who could not get a transplant are now able to get the transplant because of these improvements in the laboratory.

20:01 Outro

Resources: 

• National Marrow Donor Program
• United Network for Organ Sharing 

Successful pig to human transplant articles:

• What the successful test of a pig-to-human kidney transplant means | Science News
• Kidney Grown in Pig Successfully Transplanted Into Man (webmd.com)
• A pig kidney has been transplanted into a human successfully for the first time : NPR
• Progress in Xenotransplantation Opens Door to New Supply of Critically Needed Organs | NYU Langone News
• Startup looks to begin pig-to-human organ transplants by 2022 - Big Think 

Timestamps:

00:00 Intro

01:24 Why does clinical context matter for what test clinicians order?

08:41 What determines what kind of test to order?

13:07 How does the communication happen between the lab and the clinician? How should it happen to provide best care for the patient?

18:21 What do you think about for the future of ordering laboratory tests? 

21:59 Outro

Timestamps:

00:00 Intro

00:48 What’s your origin story? How did you get interested in medical school education?

06:18 What are we learning about better ways to educate? 

13:42 How can faculty make it a safe environment? How can we get students to give it a try?

16:25 How do you bring about and navigate curricular change?

20:15 Was there something that you did that prepared you for this role? Is there some advice for people who are interested in taking a leadership role in education at their institution? 

24:04 Could you share what you think the future of medical education will look like?

28:33 Outro

Timestamps:

00:00 Intro

01:07 Why is it so challenging to ask questions in an interview?

03:19 Can you go over what are a few aspects that somebody can ask about?

04:41 What was your process when you made your list, that cheat sheet, the actual how we’re doing of formulating a question. What was your approach there?

05:54 Are there any interesting questions you’ve gotten from applicants over the years that really stood out to you? Conversely, what are some questions that you think applicants should avoid if they are going through this process?

09:41 From your perspective as an interviewer, what do you think makes for a positive experience? 

13:36 How do you think applicants can navigate “red flags” and what can the interviewer do to approach these subjects empathetically?

17:13 Is there a tip you want to convey to all medical students interviewing for pathology residency?

19:11 Outro

Timestamps:

00:00 Intro

01:22 Why is it important for labs to learn from their COVID-19 experiences?

05:34 Did you have any other lessons learned from this experience?

8:31 How are these meetings focused on maintaining a high quality? How did you manage the rest of your workload (developing new tests, etc.)?

12:51 Have some of those lessons from the experience of how those meetings were run, is there anything that you’re taking forward that you hadn’t been doing before COVID?

14:43 What do you think about those relationships between the laboratory and physicians, what have you heard from your clinical colleagues about what they’ve come to appreciate or something that they’ve learned about the laboratory that they are now taking forward in their practice?

18:25 Through this pandemic, what’s been your joy, how have you kept your heart full so that you can continue to work as hard as you have through this pandemic?

20:47 Outro

Timestamps:

00:00 Intro

01:02 What are a few of the potential risks and benefits of using social media as a professional? Why should I be doing this and thinking about it?

03:31 People can adjust their privacy settings on social media, so why is it important for healthcare professionals and students to behave professionally on social media? 

06:08 Some might say that there are several shades of gray when it comes to professionalism. So, what do we need to understand about professionalism on social media?

08:44 I understand that you have some things you’ve helped students and faculty navigate social media, can you share a few of those significant challenges with us?

13:15 What are a few tips for people just getting started?

17:38 What’s your view of professional use of social media?

19:58 Outro

Disclosure of relevant financial relationship: Dr. Mazepa received honoraria from Sanofi.

Timestamps:

00:00 Intro

00:52 Why is it important for physicians to have some understanding about TTP?

04:26 What’s new in this immune TTP area?

08:57 If you have a new patient show up, you do caplacizumab and plasma exchange together or are there certain patient populations, like certain characteristics who would or would not get this medication? 

11:29 I was wondering if you could elaborate a little bit more about these chronic complications?

16:32 Do you think there is a role for repeat testing of ADAMTS13 on these patients in chronic phase, or is that an area that is unknown at this point?

18:53 What do you see on the horizon, what do you think the future looks like for TTP?

21:36 Outro

Resources:

Stroke and TTP (Hopkins group led by Dr. Shruti Chaturvedi):  https://ashpublications.org/blood/article/134/13/1037/374919/Reduced-ADAMTS13-activity-during-TTP-remission-is

Cognitive impairment in TTP:

(Ohio State and London TTP group collaboration) https://ashpublications.org/blood/article/134/13/1037/374919/Reduced-ADAMTS13-activity-during-TTP-remission-is

(OK Registry, Dr. James George) 

https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.24060

Timestamps:

00:00 Intro

00:43 Why is it important for physicians to understand about the reversal of these direct oral anticoagulants?

03:09 The complications or the bleed rate was a lot less, with these direct oral anticoagulants?

03:57 Although there is less severe bleeding, there was a concern by patients and physicians about, if it is severe, what is the plan? 

04:51 What have we learned new? Are we learning more about what patient population to use them in, as well as the plans to reverse them?

06:10 Can you elaborate a little bit about the idea for weekly monitoring for INR, why is it a big deal? 

7:44 Could you give us an example of where it wouldn’t be ideal to do home INR monitoring for a given patient?

09:06 Are there updates to what the reversal plans are, and how have they changed recently?

12:34 Are there still some challenges that remain for reversing these direct oral anticoagulants?

19:54 What do you think the future looks like for anticoagulant reversal? 

23:47 Outro

Resources:

https://pubmed.ncbi.nlm.nih.gov/30916798/